Measuring risk in end-stage renal disease: Is N-terminal pro brain natriuretic peptide a useful marker?
- 1 March 2007
- journal article
- editorial
- Published by Elsevier in Kidney International
- Vol. 71 (6) , 481-483
- https://doi.org/10.1038/sj.ki.5002140
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- N-terminal pro brain natriuretic peptide predicts mortality in patients with end-stage renal disease in hemodialysisKidney International, 2007
- Traditional and emerging cardiovascular and renal risk factors: An epidemiologic perspectiveKidney International, 2006
- Natriuretic Peptides in ESRDAmerican Journal of Kidney Diseases, 2005
- Elimination of the Cardiac Natriuretic Peptides B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP by HemodialysisClinical Chemistry, 2004
- B-Type Natriuretic Peptide and Renal DiseaseHeart Failure Reviews, 2003
- Circulating Natriuretic Peptide Concentrations in Patients With End-Stage Renal Disease: Role of Brain Natriuretic Peptide as a Biomarker for Ventricular RemodelingMayo Clinic Proceedings, 2001
- B-type natriuretic peptide levels: A potential novel “white count” for congestive heart failureJournal of Cardiac Failure, 2001
- Natriuretic PeptidesNew England Journal of Medicine, 1998
- Superiority of Brain Natriuretic Peptide as a Hormonal Marker of Ventricular Systolic and Diastolic Dysfunction and Ventricular HypertrophyHypertension, 1996
- The natriuretic peptide familyCurrent Opinion in Nephrology and Hypertension, 1993